Temporal lobe epilepsy, which results in recurring seizures and cognitive dysfunction, is associated with premature aging of ...
Scientists have identified an “epilepsy belt” that stretches across the U.S. south. Researchers looked at data from nearly 5 ...
The risk for a diagnosis of epilepsy is more than two times greater for those with depression, although incidence is low, ...
Clearing out “aged” brain cells dramatically reduced seizures and restored memory in a new epilepsy study.
Emerging clinical and autopsy evidence points to late-onset epilepsy as a potentially distinct, neurodegeneration-related form of epilepsy, with many cases still unexplained.
Researchers caution that while the findings are promising, the observational study does not prove that GLP-1 drugs prevent ...
Stocktwits on MSN
Biohaven’s phase II depression trial falls short, but analysts downplay impact – Wall Street looks ahead to epilepsy data
Analyst Myles Minter noted that the company’s pivotal Phase III study of BHV-7000 in focal-onset epilepsy in the first half ...
This is the latest study to suggest that GLP-1s, particularly semaglutide, are tied to a reduced risk for epilepsy in type 2 diabetes.
A new study suggests temporal lobe epilepsy may be linked to early aging of certain brain cells. When researchers removed these aging cells in mice, seizures dropped, memory improved, and some animals ...
Videos that present inaccurate and potentially harmful information about epilepsy drew more views on TikTok than accurate ...
Several risk factors may impact the long-term outlook for individuals with epilepsy, such as being over age 60 years, having a brain infection, having a family history of seizures, and having a health ...
A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback